Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset

Sarah B. Lieber,1,2 Iris Navarro-Millán,1,2 Mangala Rajan,2 Jeffrey R. Curtis,3 Sebastian E. Sattui,4 Geyanne Lui,5 Sergio Schwartzman,1,2 and Lisa A. Mandl1,2

Objective. Frailty is associated with disability and mortality independent of age. Although studies have evaluated frailty in rheumatoid arthritis (RA), information on the prevalence of frailty in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) is limited. We aimed to determine the prevalence of frailty in AS and PsA and to evaluate whether characteristics known to be associated with frailty, including anxiety, differ among these three types of inflammatory arthritis.

Methods. We performed a cross sectional study of Centers for Medicare & Medicaid Services (CMS) beneficiaries aged 65 years or older with AS, PsA, or RA enrolled in 2014. We operationalized frailty using a validated claims-based frailty index. We also explored the prevalence of frailty among CMS beneficiaries younger than age 65 years with work disability, a younger population that also may be at risk of frailty.

Results. The prevalence of frailty in beneficiaries aged 65 years or older with AS and PsA was 45.2% and 46.7%, respectively, significantly lower than in RA (65.9%, P < 0.05). The prevalence of frailty in beneficiaries less than 65 years old was much lower overall, though still highest in RA; 11.7%, 4.4%, and 7.0% in RA, AS, and PsA, respectively (P < 0.05). Anxiety was significantly associated with frailty in subjects of all ages, particularly among those less than 65 years old (P < 0.05).

Conclusion. Almost half of beneficiaries with AS or PsA aged 65 years old or older were frail, higher than in younger disabled beneficiaries. Further studies are needed to understand the risks of developing frailty in these diseases. Frailty was associated with anxiety, particularly in the younger age groups.

Frailty, a state of decreased homeostatic reserve, is known to be associated with morbidity and mortality in the elderly (1) and has been associated with other adverse health outcomes, as well as increased healthcare utilization (2). Frailty is an important independent risk factor for disability in rheumatoid arthritis (RA) (3). Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are types of spondyloarthritis (SpA) that preferentially affect younger people and, when poorly controlled, lead to increased disability and worse health-related quality of life (4). AS and PsA often lead to impairment during prime working years and have been associated with decreased workplace productivity and early retirement (4). Limited preliminary data from a single-center cross-sectional study of patients with multiple types of SpA (including AS, PsA, undifferentiated SpA, and SpA associated with inflammatory

This study was supported by a Seed Grant for Innovative Primary Care from Weill Cornell Medicine and a P30 BIGDATA core grant from the National Institutes of Health P30AR072583. Dr. Lieber was supported by a Scientist Development Award from the Rheumatology Research Foundation and a Michael D. Lockshin Fellowship from the Barbara Volcker Center for Women and Rheumatic Diseases at the Hospital for Special Surgery. Dr. Navarro-Millán was supported by the K23AR068489 award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. 

1Sarah B. Lieber, MD, MS, Iris Navarro-Millán, MD, MSPH, Sergio Schwartzman, MD, Lisa A. Mandl, MD, MPH: Hospital for Special Surgery, New York, New York; 2Sarah B. Lieber, MD, MS, Iris Navarro-Millán, MD, MSPH, Mangala Rajan, MBA, Sergio Schwartzman, MD, Lisa A. Mandl, MD, MPH: Weill Cornell Medicine, New York; 3Jeffrey R. Curtis, MD, MS, MPH: University of Alabama at Birmingham, Birmingham, Alabama; 4Sebastian E. Sattui, MD: University of Pittsburgh, Pittsburgh, Pennsylvania; 5Geyanne Lui, BS: New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York. Sarah B. Lieber has received research and salary support through the K23-AR068489 award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

© 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
bowel disease) compared with RA suggest that the prevalence of frailty is similar in both conditions (5). This study defined frailty according to the Fried frailty phenotype (1), which is measured at point of care and therefore cannot be applied retrospectively to large population-based cohorts. However, a claims-based frailty index (CFI) has been developed and validated for use in administrative datasets (6).

The aim of this study was to determine prevalence of frailty in Centers for Medicare & Medicaid Services (CMS) beneficiaries with AS or PsA compared with those with RA. We also evaluated differences in anxiety and fibromyalgia among frail and non-frail patients with RA, AS, and PsA. Anxiety and fibromyalgia are known to be associated with frailty and may help provide face validity for the CFI in patients with inflammatory arthritis (7,8). We also explored frailty prevalence and these associated characteristics among patients with AS, PsA, or RA enrolled in CMS Social Security Disability Insurance (SSDI). SSDI provides Medicare benefits among patients with AS, PsA, or RA enrolled in CMS Social Security Disability Insurance (SSDI).

PATIENTS AND METHODS

Study design. This is a cross-sectional study of CMS beneficiaries who were enrolled in 2014.

Inclusion criteria. We included individuals 18 years of age or older with International Classification of Diseases, Ninth Revision (ICD-9) codes for AS (ICD-9-CM 720.0x), PsA (ICD-9-CM 696.0x, 696.1x [only if another code for 696.0x available]), or RA (ICD-9-CM 714.xx), coded by a rheumatologist on at least 2 occasions at least 7 days apart (9). All participants were continuously enrolled in Medicare Part A and B and not in Part C (Medicare Advantage) for the entire 12 months of 2014.

Exclusion criteria. We excluded individuals who had an ICD-9 code for systemic lupus erythematosus, inflammatory bowel disease (IBD), cancer, human immunodeficiency virus, end stage renal disease, or organ transplantation or who were coded as having met inclusion criteria for more than one of AS, PsA, or RA.

Frailty definition. Frailty was operationalized using a validated ICD-9 CFI (6). This index includes variables such as age, impaired mobility, recent admission, falls, and comorbid conditions and has been shown to identify individuals with the Fried frailty phenotype, a widely accepted frailty metric (1,6) (Table S1). The CFI incorporates a weighted arthritis component, which includes ICD-9 codes for RA; a weighted Charlson-Deyo comorbidity index (CCI) component, which includes ICD-9 codes for RA (10); and a weighted musculoskeletal problems component, which includes ICD-9 codes for AS (6). We excluded ICD-9 codes for RA, AS, and PsA when calculating the CFI and CCI for this study. We chose a CFI cut point of 0.12 to identify frailty as suggested by Segal et al to maximize sensitivity and specificity at 66% and 73%, respectively (6).

Sociodemographic and comorbid variables. Age, sex, and race/ethnicity were extracted from the CMS files. We used the CCI as a measure of disease burden (10). The CCI is a weighted index originally designed to predict risk of death within 1 year of hospitalization for patients with specific comorbid conditions, including RA and osteoarthritis, but not AS or PsA. We also evaluated whether anxiety and fibromyalgia differed between frail and non-frail beneficiaries, as both have been associated with frailty in other populations (7,8). Anxiety and fibromyalgia are found neither in the CCI nor in the

Table 1. Characteristics of study participants

| Characteristic      | <65 Years Old (N = 59,087) | ≥65 Years Old (N = 238,090) |
|---------------------|-----------------------------|----------------------------|
| Age (y), Mean ± SD  | N = 2,490                   | N = 17,779                  |
| Female, %           | 31.6 (52.8 ± 8.6)           | 60.5 (72.5 ± 5.8)          |
| Race/ethnicity, %   | N = 49,647                  | N = 217,561                |
| African American    | 9.0 (15.7)                  | 3.5 (7.4)                  |
| White               | 75.8 (68.9)                 | 88.1 (84.0)                |
| Hispanic            | 8.9 (15.7)                  | 3.9 (5.1)                  |
| Other               | 6.3 (4.2)                   | 4.5 (3.4)                  |
| CCI Score, %        | N = 2,750                   | N = 217,561                |
| 0                   | 43.8 (31.0)                 | 31.6 (26.8)                |
| 1-4                 | 53.9 (64.8)                 | 62.2 (66.0)                |
| ≥5                  | 2.3 (5.9)                   | 6.2 (7.2)                  |
| Frail, %            | 4.4 (11.7)                  | 45.2 (46.7)                |

Abbreviations: AS, ankylosing spondylitis; CCI, Charlson-Deyo comorbidity index; PsA, psoriatic arthritis; RA, rheumatoid arthritis.
CFI, and a high prevalence of these conditions would provide face validity for the CFI in this patient population.

**Statistical methods.** We used descriptive statistics to describe our cohort. We compared the frailty prevalence among individuals with AS, PsA, or RA, separately for CMS beneficiaries 65 years of age and older and CMS SSDI beneficiaries less than 65 years old. For each rheumatic condition, we also compared the prevalence of variables included in the CFI, as well as the prevalence of anxiety and fibromyalgia between frail and non-frail beneficiaries. We used Chi-Square tests and analysis of variance to determine differences in frailty components among AS, PsA, and RA. Within each age group, we used logistic regression to determine the odds of frailty in patients with AS and PsA compared with patients with RA. As multiple sociodemographic features and comorbid conditions were included in the frailty index, we chose not to adjust for potential confounding factors to avoid overfitting. All analysis was done using SAS 9.4 (Cary, NC).

**Ethical oversight.** This study was approved by the Institutional Review Board of Weill Cornell Medicine.

## RESULTS

**Study sample**

A total of 297,177 Medicare enrollees were included in this analysis; 5,240 (1.8%) with AS, 24,729 (8.3%) with PsA, and 267,208 (90%) with RA (Figure S1).

### Medicare beneficiaries less than 65 years old

**Sociodemographic characteristics.** Individuals with AS or PsA were younger (mean age: 71.9 ± 5.4 and 72.5 ± 5.8 years, respectively) than those with RA (mean age: 74.7 ± 6.7 years, \( P < 0.05 \)) and were less often female (34.5% and 60.7%, respectively, vs. 76.1%, \( P < 0.05 \)) (Table 1). Most individuals were White. Individuals with AS or PsA had significantly less comorbidity than those with RA (\( P < 0.05 \)).

**Frailty and associated characteristics.** Frailty was common in all three rheumatic diseases, but significantly less prevalent in those with AS (45.2%) or PsA (46.7%) compared with those with RA (65.9%) (\( P < 0.05 \)) (Table 1). Urinary tract

---

### Table 2. Frailty components and associated characteristics of participants*

| Characteristic                        | <65 Years Old (N = 59,087) | ≥65 Years Old (N = 238,090) |
|---------------------------------------|-----------------------------|-----------------------------|
|                                       | AS Frail (109) | Non-Frail (489) | AS Frail (1,244) | Non-Frail (8,296) | AS Frail (143,435) | Non-Frail (25,939) |
|                                       | PsA Frail (159) | Non-Frail (5,811) | PsA Frail (1,244) | Non-Frail (8,296) | PsA Frail (143,435) | Non-Frail (25,939) |
|                                       | RA Frail (489) | Non-Frail (5,811) | RA Frail (1,244) | Non-Frail (8,296) | RA Frail (143,435) | Non-Frail (25,939) |
| Impaired mobility                     | 2.8 0.1       | 2.5 0.1       | 2.3 0.1       | 0.3 0.0       | 0.2 0.0       | 0.4 0.0       |
| Depression                            | 56.0 26.0     | 64.2 35.2     | 61.6 28.1     | 23.2 5.9     | 27.8 8.2     | 22.3 5.1     |
| Congestive heart failure              | 46.8 2.7      | 43.2 3.1      | 36.4 2.3      | 19.9 0.9     | 18.4 0.6     | 16.6 0.3     |
| Parkinson’s disease                   | 4.6 0.4       | 2.3 0.3       | 1.7 0.2       | 3.4 0.3      | 2.3 0.2      | 1.6 0.2      |
| Cognitive impairment                 | 7.3 0.9       | 8.0 1.7       | 8.2 1.0       | 6.8 0.6      | 7.7 0.6      | 8.4 0.4      |
| Stroke                                | 19.3 1.8      | 17.2 2.1      | 16.0 1.9      | 8.3 1.5      | 9.3 0.8      | 8.5 0.7      |
| Paranoia                              | 12.8 4.0      | 11.5 3.9      | 8.8 2.3       | 3.2 0.3      | 3.4 0.3      | 3.1 0.3      |
| Chronic skin ulcer                    | 16.5 2.1      | 21.1 3.2      | 16.6 3.1      | 7.9 1.3      | 8.6 1.4      | 9.5 1.4      |
| Pneumonia                             | 18.4 2.5      | 19.2 4.1      | 21.4 4.5      | 10.8 1.7     | 9.7 2.1      | 11.0 2.4     |
| Skin/soft tissue infection            | 23.9 9.7      | 38.5 14.5     | 30.2 11.3     | 16.7 6.0     | 19.4 8.1     | 16.8 6.0     |
| Mycoses                               | 31.2 10.1     | 43.2 14.3     | 33.5 11.7     | 26.1 11.6    | 28.5 10.6    | 25.8 7.9     |
| Recent admission                      | 35.8 5.8      | 33.7 6.6      | 31.9 6.9      | 14.4 3.5     | 15.1 3.5     | 15.2 3.2     |
| Crystalline arthropathy               | 11.0 4.8      | 15.3 5.7      | 12.3 3.8      | 13.5 6.6     | 14.0 7.2     | 9.6 4.1      |
| Falls                                 | 11.9 3.8      | 13.7 3.8      | 11.5 3.6      | 8.0 1.9      | 8.4 1.9      | 8.8 2.3      |
| Urinary tract infection               | 27.5 9.4      | 35.0 14.1     | 33.2 14.6     | 22.8 8.7     | 26.2 11.6    | 27.5 12.1    |
| Anxiety                               | 39.5 19.8     | 41.5 27.5     | 37.4 22.1     | 14.3 5.7     | 17.8 8.1     | 15.3 7.6     |
| Fibromyalgia                          | 61.5 40.8     | 56.9 41.7     | 58.4 41.8     | 32.6 18.5    | 28.4 17.6    | 27.2 18.0    |

Abbreviations: AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.

*\( P < 0.05 \) for all comparisons between frail and non-frail participants by age and disease classification.
infections, mycoses, and depression were the most common frailty components (Table 2).

Anxiety and fibromyalgia were significantly more common among frail versus non-frail beneficiaries in all three rheumatic conditions (Table 2): Prevalence of anxiety was 14.3% versus 5.7% in AS, 17.8% versus 8.1% in PsA, and 15.3% versus 7.6% in RA ($P < 0.05$ for all comparisons) (Table 2). The prevalence of fibromyalgia was 32.6% versus 18.5% in AS, 28.4% versus 17.6% in PsA, and 27.2% versus 18.0% in RA ($P < 0.05$ for all comparisons). The likelihood of frailty was lower in beneficiaries with AS (odds ratio [OR] 0.43; 95% confidence interval [CI] 0.40-0.46) and PsA (OR 0.45, 95% CI 0.44-0.47) relative to beneficiaries with RA (Table 3).

### SSDI beneficiaries less than 65 years old

**Sociodemographic characteristics.** SSDI beneficiaries less than 65 years old with AS or PsA were significantly younger (mean age: 50.3 ± 9.4 and 52.8 ± 8.6 years, respectively) than those with RA (mean age: 54.9 ± 7.9 years, $P < 0.05$) and were less often female (31.6% and 60.5% vs. 78.1%, $P < 0.05$) (Table 1). Likewise, most individuals were White, and those with AS or PsA had a significantly lower comorbidity burden than those with RA ($P < 0.05$).

**Frailty and associated characteristics.** Frailty was much less common in this younger cohort with work disability. Similar to the older cohort, frailty was significantly more prevalent in beneficiaries with RA compared with AS and PsA (11.7%, 4.4%, and 7.0%, respectively; $P < 0.05$; Table 1). In contrast to those aged 65 or older, the most prevalent frailty component in those less than 65 years old was depression in all rheumatic conditions (56.0% in AS, 64.2% in PsA, and 61.6% in RA) (Table 2).

Similar to the older cohort, anxiety and fibromyalgia were also more common in frail versus non-frail individuals in all three conditions (anxiety: 39.5% vs. 19.8% in AS, 41.5% vs. 27.5% in PsA, and 37.4% vs. 22.1% in RA; fibromyalgia: 61.5% vs. 40.8% in AS, 56.9% vs. 41.7% in PsA, and 58.4% vs. 41.8% in RA; $P < 0.05$ for all comparisons) (Table 2). Odds of frailty were lower in AS (OR 0.35, 95% CI 0.29-0.42) and PsA (OR 0.57, 95% CI 0.52-0.63) relative to RA, a similar trend as seen in those 65 years of age or older (Table 3).

### DISCUSSION

In this large cross-sectional sample of Medicare beneficiaries, patients with AS or PsA were less likely to be frail than those with RA, whether they were aged 65 years or older or less than 65 and work disabled. However, Medicare enrollees with AS and PsA had a greater than 4-fold higher frailty prevalence compared with the 11% prevalence of frailty in Medicare enrollees participating in the Cardiovascular Health Study, which determined frailty using the same CFI (6). This suggests that frail patients with AS and PsA could have similar increased risk of death, time to death, number of hospital admissions, and number of nursing home admissions as other frail Medicare enrollees 65 years of age or older (6).

To our knowledge, the prevalence of frailty in patients with SpA has been assessed in only one prior cross-sectional cohort (5). That study included a mix of 523 subjects with a heterogeneous group of patients with SpA (AS, PsA, undifferentiated SpA, and IBD-associated SpA); frailty was defined according to the Fried frailty phenotype. In that study, 37% of the subset of patients with SpA 65 years of age or older were frail, similar to our estimates of 45.2% and 46.7% for patients with AS and PsA, respectively (5). The prior study also evaluated frailty in RA, but the authors reported a much lower prevalence of frailty in their subset of individuals with RA who were 65 years of age or older (42% vs. 65.9% in our study) (5). Why there is a divergence in the proportion of patients with RA categorized as frail using the Fried definition versus the CFI in older beneficiaries, compared with estimates in patients with SpA, requires further study.

Prior cohort studies have evaluated younger patients with RA, and most have found similar ranges of frailty as the 11.7% found in our cohort of beneficiaries with RA less than 65 years of age. For instance, one cohort with a mean age of 58.0 years found a prevalence of 13% using the Fried frailty phenotype (3). In a second cohort with a mean age of 59.2 years among patients with RA, 18.6% of participants were frail according to the Fried frailty phenotype (11). A third study using the Survey of Health, Aging and Retirement in Europe Frailty Index, another phenotypic definition of frailty based on the Fried frailty phenotype, had a mean age of 50.9 years and found a frailty prevalence of 15% (12). In a fourth study—in which frailty was determined using the Comprehensive Rheumatologic Assessment of Frailty, an RA-specific cumulative deficits index, and for which the mean age was 58.5 years—moderate to severe frailty was present in 35.1% of participants (13). Further study is needed to evaluate relative performance of frailty metrics in subjects with RA less than 65 years old in association with clinical outcomes.

The prevalence of anxiety was 1.5 to 2 times higher in frail Medicare enrollees with RA, SpA, and PsA compared with those who were not frail. In another recent study of patients with RA who were aged less than 40 years, anxiety was similarly greater
among frail participants, defined according to a 5-item frailty scale, than non-frail participants (14). In an additional study of patients with RA who were at least 55 years old, symptoms of anxiety were more often reported by frail than non-frail participants, with frailty classified by the Groningen Frailty Indicator (15). To our knowledge, the higher prevalence of anxiety among frail as compared with non-frail patients with inflammatory arthritis other than RA has not been previously observed. The prevalence of anxiety in frail enrollees in this study, particularly work-disabled beneficiaries aged less than 65 years, exceeded the 8.3% prevalence of anxiety reported in Medicare enrollees in 2012 (16). The association between frailty and anxiety in patients with inflammatory arthritis needs to be explored in longitudinal studies. Whether or not the presence of mental health comorbidity may accelerate the development of frailty is unknown.

Our results should be viewed in light of several limitations. We were unable to validate the CFI directly against the Fried frailty phenotype in this specific rheumatoid disease sample. However, we used a CFI that has been validated in general CMS beneficiaries 65 years of age or older (6). Furthermore, it is unknown which frailty construct is best suited for measurement of frailty in patients with inflammatory arthritis. We also were unable to account for the effect of disease activity or medication use, including polypharmacy. Given its inclusion in the CFI, the CCI was used as a measure of disease burden; however, other comorbidity indices, such as the Rheumatic Disease Comorbidity Index, may be more highly predictive of adverse outcomes in patients with inflammatory arthritis (17). Depression is often correlated with anxiety (18), and since depression is a component of the CFI, patients classified as frail using the CFI may appear to have higher levels of anxiety than frail patients classified using other frailty metrics, though our findings are consistent with those of other studies of frail patients with RA. Likewise, age (as a component of the CFI) may impact frailty prevalence in patients 65 years of age or older versus those younger than 65 in our study. This is in addition to the risks of misclassification inherent in working with administrative data.

Our study has several strengths. We analyzed a large sample of patients with AS, PsA, and RA from the CMS, capturing a large subset of the United States population 65 years of age or older. We used a CFI that has been validated against the Fried frailty phenotype in CMS data. When calculating the CFI and CCI, we excluded inflammatory arthritis ICD-9 codes describing our target population to prevent systematic inflation of frailty prevalence in these groups. Although work-disabled SSDI beneficiaries aged less than 65 years are often removed from studies of administrative datasets due to limited generalizability, we were able to describe frailty prevalence and associated characteristics of enrollees in this population—recognizing its unique characteristics—and, to our knowledge, document for the first time important differences between frail CMS enrollees with inflammatory arthritis less than and more than 65 years old. Being able to identify frail Medicare beneficiaries is important, because frailty increases risk of adverse outcomes, including increased mortality and healthcare use (1,2). Inclusion of the CFI in risk stratification algorithms may improve risk assessment in large claim-based datasets. As frailty has been associated with other inflammatory conditions (19), this may be particularly true for frail patients with AS and PsA, who are already at an increased risk owing to their underlying disease. Further study is needed to determine the longitudinal association of frailty with adverse health outcomes in AS and PsA, including mortality, functional disability, and healthcare use.

**AUTHOR CONTRIBUTIONS**

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published.

**Study conception and design.** Lieber, Navarro-Millán, Rajan, Curtis, Sattui, Lui, Mandl.

**Analysis and interpretation of data.** Lieber, Navarro-Millán, Rajan, Curtis, Sattui, Lui, Schwartzman, Mandl.

**REFERENCES**

1. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, Chaves P, et al. Phenotype of frailty: characteristics in the women’s health and aging studies. J Gerontol A Biol Sci Med Sci 2006;61:282–6.
2. Blodgett J, Theou O, Kirkland S, Andreou P, Rockwood K. Frailty in NHANES: comparing the frailty index and phenotype. Arch Gerontol Geriatr 2015;60:464–70.
3. Andrews JS, Trupin L, Yelin EH, Hough CL, Covinsky KE, Katz PP. Frailty and reduced physical function go hand in hand in adults with rheumatoid arthritis: a US observational cohort study. Clin Rheumatol 2017;36:1031–9.
4. Nikipherou E, Ramiro S, van der Heijde D, Norton S, Moltò A, Dougdas M, et al. Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. Arthritis Care Res (Hoboken) 2018;70:1257–62.
5. Trujillo E, Arzar A, Sanchez H, Hernandez M, Garcia A, Trujillo Martin Mdm. Frailty and sarcopenia in inflammatory rheumatic disease. Arthritis Rheumatol 2019;71.
6. Segal JB, Chang HY, Du Y, Walston JD, Carlson MC, Varadhan R. Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care 2017;55:716–22.
7. Ni Mhaol von der Heijde D, Norton S, Molto A, Dougdas M, et al. Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. Arthritis Care Res (Hoboken) 2018;70:1257–62.
8. Zettel-Watson L, Arreola I, Garcia N, Montelongo J, Aquino J, Cherry B. Performance-based and self-reported frailty in older adults with and without fibromyalgia. Innov Aging 2018;2 Suppl_1:719–20. https://academic.oup.com/innovage/article/2/suppl_1/719/5170105
9. Yun H, Xie F, Delzetz E, Chen L, Yang S, Saag KG, et al. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. Br J Clin Pharmacol 2015;80:1447–57.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.
11. Cook MJ, Verstappen SMM, Lunt M, O’Neill TW. Increased frailty in people with osteoarthritis and rheumatoid arthritis and the influence of co-morbidity: an analysis of the UK Biobank cohort. Arthritis Care Res (Hoboken) 2021.

12. Haider S, Grabovac I, Berner C, Lamprecht T, Fenzl KH, Erlacher L, et al. Frailty in seropositive rheumatoid arthritis patients of working age: a cross-sectional study. Clin Exp Rheumatol 2019;37:585–92.

13. Salaffi F, Di Carlo M, Farah S, Carotti M. The Comprehensive Rheumatologic Assessment of Frailty (CRAF): development and validation of a multidimensional frailty screening tool in patients with rheumatoid arthritis. Clin Exp Rheumatol 2020;38:488–99.

14. Yoshii I, Kondo M. Clinical characteristics of frailty in Japanese rheumatoid arthritis patients. J Frailty Aging 2020;9:158–64.

15. Cleutjens F, van Moerbeke A, Boonen A, van Onna M. Frailty in relation to psycho-social factors in elderly patients with rheumatoid arthritis: a cross-sectional mixed qualitative-quantitative study. Int J Rheum Dis 2021;24:766–73.

16. Medicare-Medicaid Linked Enrollee Analytic Data Source Public Use File. Centers for Medicare & Medicaid Services. 2017. URL: https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-UseFiles/MMLEADS.

17. England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken) 2015;67:865–72.

18. Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 2001;3:244–54.

19. Chang SS, Weiss CO, Xue QL, Fried LP. Patterns of comorbid inflammatory diseases in frail older women: The Women’s Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 2010;65:407–13.